Groowe Groowe / Newsroom / JNJ
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

JNJ News

Johnson & Johnson

Global Medical Device Contract Manufacturing Market is Predicted to Cross the USD 190 Billion Mark by 2032, Owing to the Rising Demand for Advanced Healthcare Solutions | DelveInsight

globenewswire.com
TMO PFE AMGN BMY MRK DHR ABBV GOOG MSFT JNJ MDT BSX SYK EW ISRG EMR BIOX EXAS QRVO TER ADI TXN ON INTC NVDA AMD HPQ DELL IBM GE FISV ADP PAYX NOW CRM ORCL SAP ADSK CDNS SNPS AMAT INFY HPE LOGI ATHM BIIB GILD REGN VRTX AMRN AZN LLY NVS CRSP EDIT NTLA ALNY INCY XRAY COO MASI IRTC MRNA EMB ADMA ICUI HOLX LH DGX RDNT EVTC AFYA CHKP DDOG SMCI ALGN THRY PTC MCHP NXPI QCOM SWKS MU WDC STX

Cocaine Use Disorder Market Intelligence Report 2025-2032: Rapid Growth of Telepsychiatry Platforms Delivering Remote Treatment

globenewswire.com
ALKS PFE JNJ

Global Diabetic Eye Disease Devices Market Forecast (2025-2032) Featuring Strategic Analysis of Carl Zeiss, Topcon, Heidelberg Engineering, NIDEK, Canon Medical Systems and More - ResearchAndMarkets.com

businesswire.com
TOPC NC ALC BLCO JNJ

Surgical Robots Market worth $27.14 billion by 2030 | MarketsandMarkets™

prnewswire.com
ISRG STX MD SN ZBH JNJ

Medical Devices Market Worth USD 955 Billion by 2030 as Conventional Devices Lead and AR/VR Platforms Grow at 7.78% CAGR, Says Mordor Intelligence

globenewswire.com
MDT GEHC PHG ABT HON ZBH SYK JNJ

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

globenewswire.com
JNJ

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

prnewswire.com
JNJ

Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma

prnewswire.com
JNJ REGN

Senior Pharma and Biotech Leaders to Convene for Industry Forum at San Francisco CEO Ahead of JP Morgan Healthcare Conference

accessnewswire.com
JPM JNJ AMGN MRK BMY REGN

Medical Aesthetic Devices Market Projected to Reach $37.9 Billion by 2029

globenewswire.com
JNJ BHC ABBV